Delivery Order SPE2DB20D1109-SPE2DB25FP56H
- Not listed
- The Defense Logistics Agency awarded a $19,989.93 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-unit packages). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 31, 2025, to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Biktarvy is an antiretroviral medication used in HIV treatment, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside delivery order carries a ceiling value of $15,248.99 and is scheduled for completion by August 12, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $26,682.54 and an ultimate completion date of August 11, 2025. The contract was competitively awarded without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Biktarvy is an antiretroviral...
- The Defense Logistics Agency awarded a delivery order valued at $8,740.92 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Biktarvy is an antiretroviral medication used in HIV treatment, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $11,499.73 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (quantity 30) on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $5,907.98 and an ultimate completion date of July 22, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $18,577.92, with an ultimate completion date of August 15, 2025. The contract is non-set-aside and represents a competitive award under the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $34,787.81 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 25, 2025. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $29,406.51 to AmerisourceBergen Drug Corp for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract has an ultimate completion date of July 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Biktarvy is an antiretroviral medication used in HIV treatment, reflecting the critical pharmaceutical supply...
- The Defense Logistics Agency awarded a $35,074.07 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 13, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP56HDelivery Order
The Defense Logistics Agency awarded a $20,611.42 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price contract with no set-aside designation, utilizing competitive procurement procedures. The contract is set to be completed by August 13, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Biktarvy is a prescription antiretroviral medication used in the treatment of HIV infection. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems by supplying a comprehensive range of pharmaceuticals, medical devices, vaccines, and specialized healthcare commodities. The parent IDC represents a significant global pharmaceutical support vehicle enabling the company to fulfill diverse military healthcare requirements across multiple therapeutic domains on a worldwide basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 8/12/25 |